The discovery of a novel protein–protein interaction surface in nsp1 and Pol α opens up the possibility of developing small‐molecule inhibitors aimed at disrupting their association, which might be of therapeutical value in the treatment of COVID‐19. This evidence concerns the gene SH2D3A and COVID-19.